Vertex Pharmaceuticals Incorporated VRTX ranks 73rd in trading volume with 11.50 billion shares exchanged on May 13 2025

On May 13, 2025, Vertex Pharmaceuticals Incorporated (VRTX) closed with a trading volume of 11.50 billion, ranking 73rd in the day's stock market. The stock price of Vertex Pharmaceuticals Incorporated (VRTX) fell by 1.68%.

Vertex Pharmaceuticals Incorporated (VRTX) has announced that it will be hosting a conference call to discuss its first-quarter financial results. The call is scheduled for May 13, 2025, at 8:30 AM Eastern Time. During the call, Vertex's management team will provide an overview of the company's financial performance for the quarter, as well as discuss its strategic initiatives and outlook for the remainder of the year.

Vertex Pharmaceuticals Incorporated (VRTX) has received approval from the U.S. Food and Drug Administration (FDA) for its new drug, VX-147, which is designed to treat a rare genetic disorder. The approval marks a significant milestone for Vertex, as it expands the company's portfolio of treatments for rare diseases. VX-147 is expected to be launched in the second half of 2025, and Vertex is already in discussions with payers to ensure broad access to the new therapy.

Vertex Pharmaceuticals Incorporated (VRTX) has entered into a strategic collaboration with a leading biotechnology company to develop new treatments for cystic fibrosis. The collaboration will focus on identifying and validating new drug targets, as well as conducting preclinical and clinical studies to advance potential therapies. The partnership is expected to accelerate Vertex's research and development efforts in cystic fibrosis, and could lead to the development of new treatment options for patients with this debilitating disease.